JP2010526034A5 - - Google Patents

Download PDF

Info

Publication number
JP2010526034A5
JP2010526034A5 JP2010504215A JP2010504215A JP2010526034A5 JP 2010526034 A5 JP2010526034 A5 JP 2010526034A5 JP 2010504215 A JP2010504215 A JP 2010504215A JP 2010504215 A JP2010504215 A JP 2010504215A JP 2010526034 A5 JP2010526034 A5 JP 2010526034A5
Authority
JP
Japan
Prior art keywords
composition
dendritic cells
polynucleotide
shrna
desired antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010504215A
Other languages
English (en)
Japanese (ja)
Other versions
JP5565906B2 (ja
JP2010526034A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/060479 external-priority patent/WO2008131006A2/en
Publication of JP2010526034A publication Critical patent/JP2010526034A/ja
Publication of JP2010526034A5 publication Critical patent/JP2010526034A5/ja
Application granted granted Critical
Publication of JP5565906B2 publication Critical patent/JP5565906B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010504215A 2007-04-16 2008-04-16 スカベンジャー受容体−ａを抑制する方法および抗原への免疫応答を増大する方法 Expired - Fee Related JP5565906B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92362807P 2007-04-16 2007-04-16
US60/923,628 2007-04-16
PCT/US2008/060479 WO2008131006A2 (en) 2007-04-16 2008-04-16 Method for inhibiting scavenger receptor-a and increasing immune response to antigens

Publications (3)

Publication Number Publication Date
JP2010526034A JP2010526034A (ja) 2010-07-29
JP2010526034A5 true JP2010526034A5 (enExample) 2011-05-19
JP5565906B2 JP5565906B2 (ja) 2014-08-06

Family

ID=39853929

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010504215A Expired - Fee Related JP5565906B2 (ja) 2007-04-16 2008-04-16 スカベンジャー受容体−ａを抑制する方法および抗原への免疫応答を増大する方法

Country Status (6)

Country Link
US (2) US8133875B2 (enExample)
EP (1) EP2147011A4 (enExample)
JP (1) JP5565906B2 (enExample)
CN (1) CN101675066A (enExample)
CA (1) CA2684278C (enExample)
WO (1) WO2008131006A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9375473B2 (en) 2010-02-19 2016-06-28 Cornell Research Foundation, Inc. Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0011571A (pt) 1999-06-24 2002-03-05 Smithkline Beecham Corp Antagonistas do receptor de limpeza de macrófago
GB9927328D0 (en) * 1999-11-18 2000-01-12 Lorantis Ltd Immunotherapy
WO2003042246A2 (en) * 2001-11-14 2003-05-22 Lorantis Limited Inhibitors of the notch signalling pathway for use in the treatment of cancer
DE602004016732D1 (de) * 2003-03-12 2008-11-06 Rappaport Family Inst For Res Zusammensetzungen und verfahren zur diagnose und behandlung einer entzündung

Similar Documents

Publication Publication Date Title
Fernandes et al. Role of telomeres and telomeric proteins in human malignancies and their therapeutic potential
Locati et al. Macrophage activation and polarization as an adaptive component of innate immunity
Pancione et al. Immune escape mechanisms in colorectal cancer pathogenesis and liver metastasis
JP2016502512A5 (enExample)
CY1118437T1 (el) Στοχευομενη απελευθερωση φαρμακων θεραπευτικων νουκλεϊνικων οξεων και λειτουργικων νουκλεϊνικων οξεων σε κυτταρα θηλαστικου μεσω ανεπαφων θανατωμενων βακτηριακων κυτταρων
MX346663B (es) Lineas de celulas de bajo nivel de fucosa y usos de las mismas.
NZ591137A (en) Methods and systems for predicting response of cells to a therapeutic agent
JP2011136997A5 (enExample)
MX2015005352A (es) Composiciones y métodos para el tratamiento de la enfermedad de parkinson mediante la administración selectiva de moléculas de oligonucleótidos a tipos específicos de neuronas.
NZ704295A (en) Compositions and methods for the treatment of infections and tumors
MX374906B (es) Nuevos inmunoconjugados
JP2012050449A5 (enExample)
JP2012506254A5 (enExample)
JP2017524348A5 (enExample)
WO2010065876A3 (en) Methods and compositions related to th-1 dendritic cells
JP2014509852A5 (enExample)
JP2018530530A5 (enExample)
JP2012515213A5 (enExample)
JP2017516458A5 (enExample)
AR082312A1 (es) Una composicion farmaceutica de combinacion para tratar diabetes y desordenes metabolicos
CN107249644A (zh) 针对转铁蛋白受体(TfR)的RNA适体
JP2022518251A (ja) 肝毒性の治療
Grandi et al. Targeting the Eph/Ephrin system as anti-inflammatory strategy in IBD
JP2020500502A5 (enExample)
Shi et al. Recent advances in single-cell profiling and multispecific therapeutics: paving the way for a new era of precision medicine targeting cardiac fibroblasts